CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...
Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, ...
Medpage Today on MSN9d
Treatment of Oligometastatic EGFR-Mutant Lung CancerEGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, ...
colorectal (colon) cancer; epidermal growth factor receptor (EGFR); RAS; liquid biopsy; rechallenge; cetuximab; RAS; ...
Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...
Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...
Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...
China’s drug regulator approved Alpha Biopharma Ltd.’s EGFR tyrosine kinase inhibitor (TKI), Zorifer (zorifertinib hydrochloride tablets; AZD-3759), as a first-line treatment for EGFR-mutated ...
Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists ...
In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback